Market News
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Solid Tumor.
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer.
- Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Epidermolysis Bullosa.
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hepatocellular Carcinoma.
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer.
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma.
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Melanoma.
- SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approvalby kgi-admin (Pharmaceutical Technology) on April 19, 2024
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer.
- Phase III SELECT-GCA Trial for Rinvoq Yields Promising Results in Treating Patients with Giant Cell Arteritisby OncLive articles on April 18, 2024
According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.
- The Real Cost of State Drug Importation Programs? Patient Safetyby OncLive articles on April 18, 2024
Importing drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
- 23andMe CEO plans to take company privateby Elise Reuter (BioPharma Dive – Latest News) on April 18, 2024
Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.
- Vertex begins bid for US approval of non-opioid painkillerby Ben Fidler (BioPharma Dive – Latest News) on April 18, 2024
The biotech has begun a rolling submission of a closely watched drug that’s important to its future, but faces questions of sales potential.
- Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s studyby Ned Pagliarulo (BioPharma Dive – Latest News) on April 18, 2024
Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.
- Coya Therapeutics CEO Discusses Recent Data Discovery from a Study of Coya 302, a Potential Treatment for ALSby OncLive articles on April 18, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides an update on the progress of Coya 302 as a treatment for ALS.
- Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novoby Ben Fidler (BioPharma Dive – Latest News) on April 18, 2024
It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.
- Mississippi Establishes Rare Disease Advisory Councilby OncLive articles on April 18, 2024
The council was established as part of NORD’s Project RDAC.
- Novo Nordisk Foundation’s SVP of Natural & Technical Sciences Discusses the Future of Quantum Sensing in Clinical Researchby OncLive articles on April 18, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation, offers her thoughts on where quantum sensing is heading when it comes to aiding treatment development and […]
- Advancing Healthcare Solutions: Harnessing Collaborative Business Models for Oncologyby OncLive articles on April 18, 2024
Unique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.